Skip to main content
Signal8

ARTIVION, INC. (AORT)

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Artivion, Inc. logo

Artivion, Inc.

NYSE:AORTHealthcare
-2.80%$23.30
AH Close$23.30+0.00%vs close
Mkt Cap$1.14B
Float45.71M
O/S48.76M
Inst Own94.2%
SI7.9%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$1.14B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership94.15%

based on 48.76M shares outstanding

SectorHealthcare
IndustryMedical - Devices
ExchangeNYSE
CountryUSUS
IPO DateFeb 12, 1993
Shares Outstanding48.76M
Float45.71M
Company Overview

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues.

Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications.

The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches.

The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Leadership

Anthony B. Semedo

Daniel J. Bevevino

Elizabeth A. Hoff

J. Patrick Mackin

Chairman, President, and Chief Executive Officer; President, Chief Executive Officer, and Chairman of the Board of Directors

Employees

2K+

Country

US

Sector

Healthcare

Website

artivion.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets available
Ratings Distribution
BUY
10
HOLD
2
SELL
0
TOTAL12
Insider Trading
InsiderTypeShares
GREEN ANDREW M profile photoGREEN ANDREW MSale11.5K
GREEN ANDREW M profile photoGREEN ANDREW MSale1.5K
GREEN ANDREW M profile photoGREEN ANDREW MSale6.5K
Mackin James P profile photoMackin James PSale70.0K
GREEN ANDREW M profile photoGREEN ANDREW MSale616
Berry Lance A profile photoBerry Lance ASale715
Shareholders
94.2%
Institutional
(210)
5.1%
Insiderⓘ
(15)
0.0%
5%+ Owners
(0)
0.8%
Unattributed (incl. retail)ⓘ
Institutional94.2%
Insider5.1%
Unattributed (incl. retail)0.8%
Sources: 13F, Form 4, 13D/13GO/S: 48.8M · as of 31 Jul 2026 · SEC cover page
Insiders & Institutional Holders
52-Week Range
$19.16$48.25
$23.30(14th percentile)
Volume
Average Daily Volume496.85K
415.35K today vs 496.85K avg(-16%)

30d Avg

496.85K

60d Avg

572.64K

90d Avg

640.66K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...